FDA Clearance Tracker · P140026-S027
ENROUTE Transcarotid Stent System
Last checked: Nov 20, 2026Latest source record: Jul 20, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jul 20, 2023
Approved
Time to decision
30 days
Received Jun 20, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140026-S027
- Device name
- ENROUTE Transcarotid Stent System
- Applicant
- Boston Scientific Corporation
- Applicant location
- Marborough, MA
- Received
- Jun 20, 2023
- Decided
- Jul 20, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P140026
Device type
- Device type
- Stent, carotid (NIM)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the ROADSTER 3 post-approval study
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.